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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER483Transcatheter Aortic Valve ReplacementJohn G. Webb, David A. Wood
Transcatheter aortic valve replacement (TAVR) is the new standard of care for patients with
symptomatic aortic stenosis who are deemed “inoperable.” Webb and Wood argue that new
data show that TAVR should also be the preferred alternative to surgical AVR in selected
high-risk, but still operable, patients. Ongoing refinement of transcatheter valve systems,
techniques, and patient selection are making TAVR an increasingly appealing option for a
broader range of moderate-risk patients.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY493Need for Pacemaker After TAVI Does Not Affect Long-Term OutcomesLutz Buellesfeld, Stefan Stortecky, Dik Heg, Sven Hausen, Ralf Mueller, Peter Wenaweser, Thomas Pilgrim,
Steffen Gloekler, Ahmed A. Khattab, Christoph Huber, Thierry Carrel, Balthasar Eberle, Bernhard Meier,
Peter Boekstegers, Peter Jüni, Ulrich Gerckens, Eberhard Grube, Stephan Windecker
Transcatheter aortic valve implantation (TAVI) causes atrioventricular-conduction
abnormalities requiring permanent pacemaker (PPM) implantation in up to 40% of patients
treated with self-expanding prostheses. Buellesfeld and colleagues sought to determine if this
affects post-TAVI clinical outcomes. Out of 353 patients, 28% required a new PPM, 14%
had a prior PPM, and 59% did not have or require a PPM. At 12 months’ follow-up, all-
cause mortality was similar in all 3 groups at about 20%. Peri-procedural PPM implantation
does not appear to adversely affect clinical outcomes among patients undergoing transfemoral
TAVI.(continued on page A-18)
AUGUST 7, 2012 (continued) A-18INTERVENTIONAL CARDIOLOGY502Subclavian Approach May Reduce Vascular Complications in TAVI ProceduresAnna Sonia Petronio, Marco De Carlo, Francesco Bedogni, Francesco Maisano, Federica Ettori,
Silvio Klugmann, Arnaldo Poli, Antonio Marzocchi, Gennaro Santoro, Massimo Napodano,
Gian Paolo Ussia, Cristina Giannini, Nedy Brambilla, Antonio Colombo
Petronio and colleagues assessed the procedural and 2-year results of the subclavian approach
for transcatheter aortic valve implantation (TAVI). Subclavian approach was used in
141 patients in the Italian CoreValve Registry who had unsuitable femoral artery anatomy
and were compared to 141 patients who underwent a femoral approach. The 2 groups
showed similar procedural success, major vascular complications, life-threatening bleedings,
and the combined safety endpoint. The subclavian group showed lower rates of acute kidney
injury stage 3 and of minor vascular complications at the 18-F sheath insertion site. These
results shows that the subclavian approach for TAVI is safe and feasible, and suggest that
subclavian access should be considered a valid option not only when the femoral approach is
impossible, but also when it is difficult.ATHEROSCLEROSIS508HDL Particle Concentration More Powerful Than Total HDL-CRachel H. Mackey, Philip Greenland, David C. Goff, Jr, Donald Lloyd-Jones, Christopher T. Sibley,
Samia Mora
Mackey and colleagues evaluated the independent associations of high-density lipoprotein
cholesterol (HDL-C) and particle (HDL-P) concentrations with carotid intima-media
thickness (cIMT) and incident coronary heart disease (CHD) in subjects enrolled in the
MESA (Multi-Ethnic Study of Atherosclerosis) trial. HDL-C and HDL-P correlated with
each other and inversely with low-density lipoprotein particle (LDL-P), cIMT, and the risk
of CHD. In a multivariable model adjusting for LDL-P, HDL-C was no longer associated
with cIMT or CHD, but HDL-P was. The authors speculate that more HDL-P may equal
higher reverse cholesterol transport capacity or the benefits may be related to HDL’s protein
or other cargo (e.g., apolipoprotein A-I, paraoxonase-1, myeloperoxidase) rather than to its
cholesterol cargo.
Editorial Comment: Emil M. deGoma, Daniel J. Rader, p. 517(continued on page A-19)




521chocardiographic RV Strain Assessment
Helps to Predict Risk of RV Failure After LVADAndrew D. M. Grant, Nicholas G. Smedira, Randall C. Starling, Thomas H. Marwick
Grant and colleagues sought to determine if quantifying pre-operative right ventricle (RV)
function would aid in predicting RV failure in patients undergoing left ventricular assist
devices (LVAD) implantation. Clinical, hemodynamic, and echocardiographic data were
collected on 117 patients prior to LVAD insertion including velocity vector imaging of RV
free wall longitudinal strain. There was a significant difference in peak strain between patients
with and without RV failure. A peak strain cutoff of 9.6% predicted RV failure with 76%
pecificity and 68% sensitivity and was incremental to the Michigan Risk Score. Measuring
V free wall peak longitudinal strain can help to identify patients at increased risk of
V failure after LVAD implantation.ditorial Comment: John P. Boehmer, p. 529ATRIAL FIBRILLATION531Left Atrial Appendage Morphology May Modify Risk of Stroke in Patients With AFLuigi Di Biase, Pasquale Santangeli, Matteo Anselmino, Prasant Mohanty, Ilaria Salvetti,
Sebastiano Gili, Rodney Horton, Javier E. Sanchez, Rong Bai, Sanghamitra Mohanty, Agnes Pump,
Mauricio Cereceda Brantes, G. Joseph Gallinghouse, J. David Burkhardt, Federico Cesarani,
Marco Scaglione, Andrea Natale, Fiorenzo Gaita
Di Biase and colleagues studied the left atrial appendage (LAA) shape by computed
tomography (CT) and/or magnetic resonance imaging (MRI) to correlate different LAA
morphologies with the risk of stroke or transient ischemia attack (TIA) in patients with atrial
fibrillation (AF). LAAs were categorized into 4 different morphologies: Cactus, Chicken
Wing, Windsock, and Cauliflower. Nearly one-half were classified as Chicken Wing with an
obvious bend in the proximal or middle part of the dominant lobe, or folding back of the
LAA anatomy. After controlling for CHADS2 score and AF type in a multivariable logistic
model, those with Chicken Wing morphology had a 79% lower risk of prior stroke/TIA.
These results suggest that LAA morphology influences the risk of stroke in patients with AF
and may play a role in guiding anticoagulation strategies of patients with a low-intermediate
CHADS2 score.(continued on page A-20)
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Shannon Carter, Dan Roden, Dawood Darbar
Recent genome-wide association studies have identified 3 loci, on chromosomes 4q25 that
associate with either typical or lone atrial fibrillation (AF). Parvez and colleagues hypothesized
that these loci may alter the efficacy of antiarrhythmic drugs (AADs) used to treat AF.
Patients had their AAD chosen without knowledge of their genetic profile. Successful rhythm
control was defined as the patient remaining on the same AAD therapy for a minimum of 6
months with 75% reduction in symptomatic AF burden. In the discovery cohort, one of the
loci was significantly associated with successful rhythm control, while clinical factors were not.
Similar findings were found in a validation cohort. These results suggest that this
polymorphism modulates response to AAD therapy and points to a potential role for
stratification of therapeutic approaches by genotype.Editorial Comment: James P. Daubert, Geoffrey S. Pitt, p. 546EXPEDITED PUBLICATION
548uality of Life Improvements With
Transcatheter or Surgical Aortic Valve ReplacementMatthew R. Reynolds, Elizabeth A. Magnuson, Kaijun Wang, Vinod H. Thourani, Mathew Williams,
Alan Zajarias, Charanjit S. Rihal, David L. Brown, Craig R. Smith, Martin B. Leon, David J. Cohen,
on behalf of the PARTNER Trial Investigators
Reynolds and colleagues compared health status and quality-of-life outcomes for patients with
severe aortic stenosis (AS) and high surgical risk randomized to either transcatheter or
surgical aortic valve replacement (TAVR or SAVR). Health status was assessed at baseline,
1, 6, and 12 months using the Kansas City Cardiomyopathy Questionnaire (KCCQ). The
KCCQ summary score improved more rapidly with TAVR, but was similar for the 2 groups
at 6 and 12 months. Further analysis showed that subjects treated with a transfemoral (TF)
approach had significant health status benefits at 1 month, whereas patients treated via the
transapical (TA) approach had no benefit over SAVR at any timepoint. These results confirm
the benefits of TAVR via the TF approach over SAVR, but the lack of benefit with the TA
approach warrants caution and further investigation.
